BPC-157

The BPC-157 evidence base cited here is 15 sources — 4 clinical, 5 preclinical, 4 review, 1 regulatory. Its strongest evidence is human — 4 clinical studies, most recently 2026 ("BPC 157 for Acute Hamstring Muscle Strain Repair — Phase 2 RCT (MRI + re…"). Regulatory status: Not FDA-approved (Category 2).

• BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein in human gastric juice, studied for accelerating repair of tendon, ligament, muscle, and bone.
• The evidence is overwhelmingly preclinical — a 2025 systematic review found 36 studies (35 animal, just 1 clinical). It is NOT FDA-approved and human data is minimal.
• Proposed mechanisms center on angiogenesis (VEGF upregulation), growth-factor/proliferation signaling, anti-inflammatory effects, and nitric-oxide modulation.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid fragment of a protective protein naturally found in human gastric fluid. It's one of the most-discussed regenerative research peptides, studied mainly for healing tendons, ligaments, muscle, and bone, plus a range of cytoprotective effects across the gut, liver, and nervous system.

The important caveat up front: nearly all of that evidence is from animal models. There is essentially no human clinical trial data, it is not FDA-approved, and it is banned in competitive sport. Everything below is research context, not medical guidance.

First described in 1992, BPC-157 is a stable fragment of the larger Body Protection Compound that occurs in gastric juice, where the parent protein helps maintain the stomach lining and GI homeostasis. The synthetic 15-mer used in research keeps that fragment's notable stability in gastric acid. The '157' is just an identifier from the original research series, not the amino-acid count (it's a 15-residue pentadecapeptide). It also appears in the literature and on labels under several development codes: Bepecin, PL10, PLD116, PL 14736, and PCO-02.

That acid stability is what makes it unusual — most peptides are destroyed by stomach acid, gut enzymes, and first-pass liver metabolism before reaching circulation, so they must be injected. BPC-157's intrinsic stability is why oral and sublingual routes are even on the table, though whether oral dosing reaches distant injury sites at meaningful levels is still an open question.

By the numbers it is a small ~1,419 Da pentadecapeptide. Pharmacokinetics are preclinical, but reported figures put the peak at roughly 1 hour, a short half-life of about 4 hours, and near-complete clearance within ~20 hours — which is the rationale behind once- or twice-daily dosing in research protocols.

There is no approved dosing for BPC-157. The figures below are what appears in research literature and anecdotal use, included for research context only.

• Low: ~200–250 mcg once daily
• Moderate: ~250–500 mcg once or twice daily
• Higher: ~500–800 mcg once or twice daily
• Animal-extrapolated human-equivalent ≈ 1.6 mcg/kg (roughly 110–145 mcg for a 150–200 lb person, oral)
• Commonly cycled ~4–8 weeks (some use 4 on / 2–4 off); shorter 2–4-week runs for acute injury

Preclinical safety was favorable — no toxic or lethal dose was reached across 6 µg/kg to 20 mg/kg in animal studies. That does not establish human safety; human data is minimal.

• Weeks 1–2: possible early reduction in inflammation/pain; some report improved mobility; oral users may note GI benefit.
• Weeks 2–4: more noticeable tissue-healing and range-of-motion gains in reports.
• Weeks 4–8: where most reported structural/functional recovery milestones cluster.

Pharmacokinetics: half-life under ~30 minutes (linear PK); metabolites detectable in urine for ~4–5 days — relevant for drug-tested athletes.

A 2025 systematic review identified 36 studies (1993–2024): 35 preclinical, 1 clinical. The animal data is consistent and encouraging; human data is the glaring gap.

Filter any BPC-157 claim through four questions — what tissue? what route? what endpoint? what proof? Pain relief is NOT the same as proven structural healing (tear closure, collagen reorganization, load-to-failure). Promising animal evidence does not guarantee the same effect or safety in humans, and the literature is unusually concentrated among a few research groups. BPC-157 remains experimental.

Often combined for recovery. Research context, not protocol advice. The most popular pairing is the so-called 'Wolverine stack.'

• BPC-157 + TB-500 (Thymosin Beta-4) — the classic recovery stack; complementary mechanisms (local healing/angiogenesis vs cell migration). Typical reported protocol: BPC-157 250–500 mcg daily; TB-500 2–2.5 mg twice weekly loading, then weekly.
• GHK-Cu — for collagen/skin-tissue quality.
• KPV — added anti-inflammatory action.
• GH secretagogues — for systemic regenerative support.

• Comes as lyophilized powder; reconstitute with bacteriostatic water added slowly down the vial wall, swirl gently (don't shake).
• Common ratio: 5 mg + 5 mL BAC water = 1 mg/mL (100 mcg per 0.1 mL / 10 units on an insulin syringe).
• Lyophilized: store below −18°C long-term (stable ~3 weeks at room temp). Reconstituted: 2–8°C, use within ~4 weeks; protect from light; avoid freeze-thaw; discard if cloudy.

Animal studies show a favorable profile with no acute toxicity across organ systems at 6 µg/kg–20 mg/kg over 6 weeks. Human safety data is extremely limited; the following are anecdotal user reports.

The FDA has flagged a possible immunogenicity risk. And because research-grade product is unregulated, contamination is a real concern — studies suggest a meaningful fraction of ergo/nutritional products are adulterated. Source quality matters.

• Not FDA-approved for any indication.
• In 2023 the FDA placed BPC-157 in the Category 2 bucket of its 503A compounding review (significant-safety-risk), so it couldn't be compounded.
• April 2026: the FDA removed BPC-157 from that Category 2 list after the nominations were withdrawn (gone from the updated document by May). Removal is NOT approval — it just changed its compounding-review status.
• July 23–24, 2026: the FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to discuss two BPC-157 forms — free base and acetate — for a proposed ulcerative-colitis use (public docket FDA-2025-N-6895). This is a review/discussion, not approval, but potentially a step toward changing its status.
• Can't legally be sold as a drug, food, or supplement for human use; sold as a 'research chemical' only. Not DEA-scheduled, so possession itself isn't illegal (unlike anabolic steroids).

Research-grade BPC-157 is for laboratory research only — not intended for human use, and from an unregulated market where identity, purity, sterility, and endotoxin contamination aren't guaranteed.

BPC-157 is explicitly banned in competitive sport. WADA added it to the Prohibited List (S0, Non-Approved Substances) in 2022; USADA, the UFC, and the NFL have specific bans, and the NCAA/MLB/PGA prohibit it under broader peptide-hormone rules. Metabolites are detectable in urine for ~4–5 days by mass spectrometry, well within testing sensitivity — tested athletes should treat it as strictly off-limits.

On the Huberman Lab podcast, internal-medicine physician Dr. Abud Bakri gave BPC-157 an unusually candid clinical framing. His central caveat: nearly all of the foundational animal data trace to a single Croatian research group (Sikiric et al., ~1991), with limited independent replication — so even the strongest preclinical claims rest on a narrow base. He characterized BPC-157 as a regenerative 'gas pedal' (driving angiogenesis and healing) rather than an anti-inflammatory.

On human data he was blunt: it amounts to roughly one or two small early-phase trials of rectal BPC enemas for ulcerative colitis (doses up to ~80 mg, versus the 100–250 mcg people inject), never fully published. BPC-157 was not detectable in blood after administration, so human pharmacokinetics are largely unknown — and Bakri suspects the popular 250 mcg injection protocols may be far too low.

On regulatory status: he noted BPC-157 was placed on the FDA's Category 2 'do not compound' list in late 2024 and removed in April 2025, and that a chemically near-identical salt is prescribed by compounding pharmacies as 'PDA' (pentadecapeptide arginate).

This section is Dr. Bakri's expert characterization on a podcast, plus widely-reported anecdote (e.g. Dr. Huberman's unusually fast recovery from a neck strain after a local ~200 mcg dose). Treat anecdotes as hypotheses to test, not as evidence.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.